IMPULSE DYNAMICS

HFSA 2025
CCM PRESENTATIONS: HIGHLIGHTS

Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations:

A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset

Presented By Daniel Burkhoff, MD at HFSA Annual Scientific Meeting, September 28, 2025. Minneapolis, MN

Authors: Daniel Burkhoff[1], Ryan Hass[2], Michael Arnold[2], Lee Ming Boo[2] From [1]Heart Failure, Hemodynamics and MCS Research, [2]Impulse Dynamics, Marlton, NJ, United States

STUDY OBJECTIVE & METHODOLOGY

What is the impact of CCM on **long-term survival** and **heart failure hospitalization**?

Study Design

Retrospective analysis using Truveta real-world database (Jan 2016 – Jun 2025)

Primary endpoints: Freedom from composite clinical outcomes at 18-months

Patient cohorts:

CCM arm **(n=218)**

Non-CCM Control **(n=387, NYHA III)**

Matched on LVEF, sex, age, race, ICD

Truveta Integrated Database

900 Hospitals

20k Clinics

120M+ US patients

EHR

Lab & imaging results

Rx data

SUMMARY OF STUDY CONCLUSIONS

Disclaimer: The effect of CCM on hospitalization or mortality has not evaluated by the US FDA and has not been studied in RCTs

PRIMARY ENDPOINT: CCM VS CONTROL COMPARISON

All-cause mortality | Heart failure hospitalization | Progression to LVAD/ heart transplant

43% Lower risk

CCM therapy resulted in **43% lower risk** of all-cause mortality, HF hospitalization, progression to LVAD/heart transplant

HR: **0.5704** P-value (Log-Rank): **0.002**

Primary endpoint was significantly better in **CCM patients (77%) than matched control (64%)** at 18-month



77% CCM

64% Control

Burkhoff et. al. Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset. Presented at HFSA Annual Scientific Meeting, September 28, 2025. Minneapolis, MN